FDA Approves Pembrolizumab for First-line Treatment of HNSCC
FDA also expanded the intended use for the PD-L1 IHC 22C3 pharmDx kit to include use as a companion diagnostic for selecting patients with HNSCC
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1549 results
Multi-omics Study of Gut Microbiota in Colorectal Cancer
Shifts in microbiome and metabolome occur early in colorectal cancer development
Triple Combined Therapy in BRAF-Mutated Melanoma
Combinations of immune checkpoint inhibitor and targeted therapies show tolerability and promising efficacy
FDA Approves Lenalidomide for Follicular and Marginal Zone Lymphoma
Approval is based on evidence from AUGMENT and MAGNIFY trials
Targeting DNA Repair in Metastatic Pancreatic and Prostate Cancers
PARP inhibitors benefit observed beyond treatment for breast and ovarian cancers
FDA Approves Addition of Survival Data to Gilteritinib Label for Refractory AML With a FLT3 Mutation
Approval is based on evidence from the ADMIRAL trial
GITR Is an Attractive Target for Immunotherapy
Targeting alternative immune pathways
EMA Grants a Positive Opinion for LysaKare (Arginine/lysine)
It is intended for protecting the kidneys against radiation during PRRT with lutetium (177Lu) oxodotreotide.
FDA Approves Alpelisib for Metastatic Breast Cancer
It also approved the companion diagnostic test to select patients who have PIK3CA mutations in tumour tissue specimens and/or in ctDNA
Combination Immunotherapies for Immune Hot, Altered and Cold Tumours
Understanding underlining mechanisms is crucial to boost a weak antitumour immunity
FDA Approves Ruxolitinib for Acute Graft-Versus-Host Disease
It is approved for steroid-refractory GVHD in adult and paediatric patients 12 years and older
IMMUNOTARGET Registry in Advanced NSCLC With Oncogenic Driver Alterations
Patients with actionable tumour alterations should receive targeted therapies and chemotherapy before considering immunotherapy